Table 6.
Twenty-one patients with positive anti-ds-DNA Abs after IFX
| anti-DNA | ANA | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| age/sex | before | after | before | after | EULAR response | symptoms | IFX | following biologics | |
| 1 | 51/F | < 2 | 300 | 40 | 320 | No | Discontinue | ADA- > TOC*4 | |
| 2 | 41/F | 6 | 300 | 320 | 320 | No | Discontinue | ETN | |
| 3 | 45/F | 51 | 300 | 160 | 320 | No | SLE like*1 | Discontinue | ETN |
| 4 | 32/F | NA | 52 | 320 | 1280 | No | |||
| 5 | 31/F | 5 | 42 | 80 | 160 | No | SLE like*2 | Discontinue | ETN |
| 6 | 36/F | 5 | 38 | 40 | 1280 | No- > good | PSL 20 mg iv*3 | ||
| 7 | 43/F | 4 | 26 | 160 | 640 | No | Discontinue | TOC | |
| 8 | 56/F | 3 | 26 | 80 | 160 | No- > good | PSL 20 mg iv*3 | ||
| 9 | 62/M | 21 | 25 | 80 | 80 | Good | PCP | Discontinue | TOC |
| 10 | 65/F | 2 | 23 | 160 | 160 | No | Discontinue | TOC- > ETN*5 | |
| 11 | 52/F | NA | 22 | NA | 160 | No | |||
| 12 | 56/M | < 2 | 20 | 320 | 320 | No | allergy | Discontinue | ETN |
| 13 | 33/F | 5 | 19 | 40 | 80 | No | |||
| 14 | 51/F | < 2 | 13 | 40 | 80 | Mod | |||
| 15 | 56/M | < 2 | 11 | 160 | 160 | No- > mod | PSL 20 mg iv*3 | ||
| 16 | 75/F | < 2 | 11 | < 40 | 320 | No | Discontinue | ETN | |
| 17 | 58/F | 11 | 11 | 80 | 640 | Mod | |||
| 18 | 30/M | < 2 | 10 | 80 | 80 | No | Discontinue | ETN | |
| 19 | 35/F | < 2 | 10 | 80 | 80 | Good | |||
| 20 | 40/F | 3 | 8 | 80 | 160 | No | Discontinue | ETN | |
| 21 | 59/F | NA | 7 | NA | 640 | Mod | |||
anti-DNA, anti-ds-DNA antibodies; ANA, antinuclear antibodies; IFX, infliximab; SLE, systemic lupus erythematosus; PCP; pneumocystis jirovecii pneumonia; PSL, prednisolone; iv, intravenous injection; ADA, adalimumab; ETN, etanercept; TOC, tocilizumab; *1, leukocytopenia and alopecia; *2, erythema; *3, premedication of each IFX administration; *4, ADA was also getting no response and successful swiched to TOC; *5, TOC ineffective, and ETN effective